AnaptysBio, Inc. (ANAB) Fair Value 2026

ANAB · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

7.0 /10

32 fundamental signals · 7 models active

Value Trap Risk

SAFE (19/100)

Quick Summary — As of 2026-08-27, AnaptysBio, Inc. (ANAB) trades at $57.29, versus a $26.35 median fair value across its 7 active models — 54.0% below the current price. QOC: 7.0/10. Value Trap Risk: 19/100 (SAFE). 7/13 models active. Within that set, the Bayesian DCF component alone returns $58.42.

Key Facts

Ticker
ANAB
Price
$57.29
Quality Score
7.0/10
Value Trap Risk
19/100
Models Active
7/13
Last Updated
Strength: Bayesian DCF suggests +2.0% upside with 58% confidence
Risk: Majority of models suggest overvaluation

Is AnaptysBio, Inc. (ANAB) Undervalued or Overvalued in 2026?

According to CirclFi’s 7-model valuation engine, AnaptysBio, Inc. (ANAB) appears overvalued as of : the median of 7 independent fair value estimates is $26.35, 54.0% below the current price of $57.29. Estimates range from $11.16 to $63.09. ANAB scores 7.0/10 on fundamental quality and 19/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.7% versus its own 13-model consensus, across 3,801 rated companies as of 2026-08-27. ANAB’s -54.0% gap is wider than that market norm, and the Biotechnology sector median is -64.8%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy AnaptysBio, Inc. Stock in 2026? →

What Fair Value Does Each Model Give ANAB?

7 Intrinsic Value Models vs. Current Price ($57.29)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $58.42 +2.0%
Ensemble · Low Conviction
 $36.24 -36.7%
Scenario · High Conviction
 $24.13 -57.9%
Unlock the Full Matrix

Access 4 additional models including Regime Cross-Sectional, Sentiment SOTP, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 7 Models →

Cancel anytime · No contracts · Instant access

What Is ANAB's Fair Value Range?

Spread across 7 independent models · $11.16 to $63.09

CirclFi's 7 active models place AnaptysBio, Inc. (ANAB) between $11.16 and $63.09 per share, a spread of 197% of the median. The median of that range — $26.35 — is the fair value CirclFi publishes for ANAB, against a current price of $57.29.

Low · Sentiment SOTPHigh · RCMH-DCF
$11.16median $26.35$63.09
Where the range comes from
Most bearish modelSentiment SOTP$11.16
Most bullish modelRCMH-DCF$63.09
Model agreement1 bullish · 5 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for ANAB. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on ANAB, not a CirclFi price target. How each model works →

What Is AnaptysBio, Inc. (ANAB) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, AnaptysBio, Inc.'s intrinsic value is estimated at a median fair value of $26.35. Trading at $57.29, the stock is approaching fair value or slight overvaluation (implied return of -54.0%), as 5 of 7 models suggest limited further upside. Notably, RCMH-DCF sees the most upside at +10.1% (fair value: $63.09), while Sentiment SOTP is the most conservative at -80.5% ($11.16). The spread between these extremes — +90.6% — reveals how different analytical frameworks can reach starkly different conclusions.

What Do the Models Say About ANAB?

7 of 13 models are currently active for ANAB. Of these, 2 models suggest upside while 5 models suggest overvaluation. Taken together, their median fair value for ANAB is $26.35 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $58.42 on its own, implying +2.0% upside from the current price. See which stocks rank higher →

How Does ANAB Rank in Biotechnology?

Among 620 Biotechnology stocks, ANAB ranks #48 by Quality of Company score. CirclFi's QOC score of 7.0/10 evaluates 32 fundamental signals. A score of 7.0 indicates above-average quality.

See all Most Undervalued Biotechnology Stocks →

The Biotechnology sector introduces analytical considerations specific to life sciences company businesses. For AnaptysBio, Inc., metrics like market exclusivity window provide important context that general-purpose valuation models may underweight.

Is ANAB a Value Trap?

CirclFi's Value Trap algorithm assigns ANAB a score of 19/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

7 of 13 models are active for AnaptysBio, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, AnaptysBio, Inc. scores 7.0 out of 10 on our 32-signal quality assessment, a solid rating that maintains reasonable quality metrics with some areas for improvement. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

The gap between the most bullish and bearish model spans +90.6% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every ANAB valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across ANAB's 7 active models, average confidence is 37%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy AnaptysBio, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

MGTXMeiraGTx Holdings plcQOC 7.0PRTAProthena Corporation plcQOC 7.0SEERSeer, Inc.QOC 7.0ADAGAdagene Inc.QOC 7.0MRNAModerna, Inc.QOC 7.0GMABGenmab A/SQOC 6.9ACETAdicet Bio, Inc.QOC 5.6REPLReplimune Group, Inc.QOC 4.8ARMPArmata Pharmaceuticals, Inc.QOC 4.1EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: MGTX · PRTA · SEER · ADAG · MRNA · GMAB · ACET · REPL · ARMP · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to ANAB?

6 companies across all industries closest to ANAB’s Quality of Company score of 7.0/10.

YRDYiren Digital Ltd.QOC 7.0HROWHarrow, Inc.QOC 7.0OCCOptical Cable CorporationQOC 7.0WHRWhirlpool CorporationQOC 7.0KEPKorea Electric Power CorporationQOC 7.0NVDANVIDIA CorporationQOC 10.0

Read investment analysis: YRD · HROW · OCC · WHR · KEP · NVDA

Where Does ANAB Sit in CirclFi's Biotechnology Rankings?

ANAB is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About AnaptysBio, Inc.’s Valuation?

What is AnaptysBio, Inc.'s intrinsic value in 2026?

CirclFi puts AnaptysBio, Inc. (ANAB)'s intrinsic value at $26.35 — the median of 7 independent model estimates as of 2026-08-27, ranging from $11.16 to $63.09. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $58.42 on its own. The Quality of Company score is 7.0/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is ANAB overvalued or undervalued right now?

At $57.29, 2 of 7 active models suggest ANAB may be undervalued, while 5 indicate potential overvaluation. The median of all 7 fair value estimates is $26.35, 54.0% below the current price of $57.29 — a consensus view that ANAB is overvalued. The assessment depends on which methodology best fits AnaptysBio, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 7.0 mean for ANAB?

AnaptysBio, Inc.'s QOC of 7.0/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on ANAB?

CirclFi analyzes ANAB with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 7 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on ANAB?

Of the 7 models currently active on ANAB, RCMH-DCF is the most bullish at $63.09 per share, and Sentiment SOTP is the most bearish at $11.16. CirclFi's published fair value for ANAB is the median of that range, $26.35, not either extreme. The gap between the two ends equals 197% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is ANAB a value trap in 2026?

AnaptysBio, Inc.'s Value Trap score is 19/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 7-model valuation engine, AnaptysBio, Inc. (ANAB) has a median fair value of $26.35 — 54.0% below the current price of $57.29 — as of 2026-08-27.” Source: circlfi.com/stock/ANAB/ · Methodology
Primary sources for this ANAB valuation
  • Financial statements: AnaptysBio, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001370053) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for ANAB as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 7 mathematical frameworks give you clarity on ANAB.

Unlock All 7 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

4 models hidden for ANAB Unlock All 7 — $39/mo